Dr. Ed Lavelle graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth. He carried out postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants.
This was followed by further postdoctoral positions at the Rowett Research Institute and Trinity College Dublin on vaccine adjuvants and immunomodulators. He was appointed as a lecturer in Immunology in 2004 and associate Professor in 2012.
His main research area is the mechanism by which particulate adjuvants modulate innate and adaptive immune responses with a strong focus on translating this work in order to develop novel adjuvants for injectable and mucosal vaccines.
His work has been published in journals including PNAS, J. Exp Med, PLos Pathogens, Nature Immunology and Immunity.
The group works closely with a number of Biotech companies and also with big Pharma engaged in vaccine research.
Dr. Lavelle has published more than 70 peer-reviewed papers, is an inventor on 5 patents and collaborates with leading academic groups throughout Europe and the U.S.
Host: Ursula Wiedermann-Schmidt
zurück zu: CePII